Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
Received 16 July 2015
Accepted for publication 19 September 2015
Published 1 December 2015 Volume 2015:9 Pages 2243—2250
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Monica Varano,1 Nicole Eter,2 Steve Winyard,3 Kim U Wittrup-Jensen,4 Rafael Navarro,5 Julie Heraghty6
On behalf of the wAMD Patient and Caregiver Survey Committee members
1Department of Ophthalmology, Fondazione GB Bietti-IRCCS, Rome, Italy; 2Department of Ophthalmology, University of Münster, Münster, Germany; 3Department of Policy and Campaigns, Royal National Institute of Blind People, London, UK; 4Bayer Pharma AG, Berlin, Germany; 5Instituto de Microcirugía Ocular, Barcelona, Spain; 6Macular Disease Foundation Australia, Sydney, NSW, Australia
Purpose: A cross-sectional survey to evaluate the current management of wet age-related macular degeneration (wAMD) and to identify barriers to treatment from a patient and caregiver perspective.
Methods: An ophthalmologist-devised questionnaire was given to a global cohort of patients who were receiving (or had previously received) antivascular endothelial growth factor injections and to caregivers (paid and unpaid) to evaluate the impact of wAMD on their lives.
Results: Responders included 910 patients and 890 caregivers; wAMD was diagnosed in both eyes in 45% of patients, and 64% had been receiving injections for >1 year. Many caregivers were a child/grandchild (47%) or partner (23%) of the patient; only 7% were professional caregivers. Most (73%) patients visited a health care professional within 1 month of experiencing vision changes and 54% began treatment immediately. Most patients and caregivers reported a number of obstacles in managing wAMD, including the treatment itself (35% and 39%, respectively). Sixteen percent of patients also missed a clinic visit.
Conclusion: Most patients seek medical assistance promptly for a change in vision; however, about a quarter of them do not. This highlights a lack of awareness surrounding eye health and the impact of a delayed diagnosis. Most patients and caregivers identified a number of obstacles in managing wAMD.
Keywords: antivascular endothelial growth factor agents, patient-reported outcomes, wAMD patient and caregiver survey, wet age-related macular degeneration
The socioeconomic burden associated with wet age-related macular degeneration (wAMD) is predicted to rise as the prevalence increases with aging populations.1–3 This will have a major impact on direct and indirect costs, including costs associated with informal care and lost productivity, which are estimated to be in the region of US$23 billion and $34 billion, respectively.4
Based on these estimates, it is essential to monitor the effectiveness of long-term management strategies with a view to identifying treatment barriers, particularly from a patient perspective. This is important for newer treatments such as antivascular endothelial growth factor (anti-VEGF) (intravitreal) injections, which have offered remarkable clinical benefits for patients with wAMD. Anti-VEGF agents are known to target a key underlying pathway in the development and progression of wAMD and have been shown to be clinically effective in large-scale studies;5–8 however, surveys on long-term treatment patterns indicate that these agents are underutilized in real-life clinical settings.9 In addition, few studies have examined the impact of anti-VEGF treatments from a caregiver perspective, with evidence suggesting that the impact may be similar to that experienced by caregivers of patients with atrial fibrillation.10 Such feedback will be invaluable for identifying any barriers to treatment provision and compliance, which could be addressed by the health provider.
The aim of this noninterventional, cross-sectional survey was to evaluate the impact of wAMD on a global cohort of patients who were currently receiving (or had previously received) anti-VEGF injections. The survey also identified caregivers (both paid and unpaid) and evaluated the effect that caring for someone with wAMD had on them. The survey was conducted via a questionnaire that was devised by ophthalmologists and experts in the field of ophthalmology. This paper reports the findings associated with current approaches to the treatment of wAMD, including diagnosis and follow-up, and obstacles to treatment, from the perspective of both patient and caregiver responders.
This was a global, noninterventional, cross-sectional survey conducted between June 2012 and September 2012, with data analysis staggered from July 2012 to December 2012. The survey was devised 1) to evaluate the emotional and physical impact of wAMD in patients and caregivers and 2) to identify current approaches to diagnosis and management of wAMD, including barriers to treatment from the perspective of patients and caregivers.
The survey was performed using a questionnaire, which was developed through collaboration between an independent steering committee consisting of ophthalmologists and experts and two research organizations (Blueprint Partnership, Manchester, UK, and Survey Sampling International [SSI], London, UK). The self-administered, 15-minute questionnaire was conducted online via the SSI website. The survey link was soft-launched, allowing a small number of responders to complete the questionnaire so that the data could be checked to ensure accurate capture. For those responders with poor eyesight, face-to-face and telephone collection methods were used, wherein a member of SSI or one of their online partners would read aloud the questions and collect and input the responders’ answers. The online, face-to-face, and telephone surveys were translated for each participating country. All responses were anonymous, and all responders provided informed consent. Approval was obtained from the relevant independent ethics committees.
The survey was conducted in nine countries (Australia, Brazil, Canada, France, Germany, Italy, Japan, Spain, and the UK). Patients with a wAMD diagnosis who were treated by a health care professional (HCP) and received current or prior anti-VEGF injections to treat their wAMD were included. Caregivers who provided care and support to a patient with wAMD (based on the aforementioned criteria) were also included. Support was defined as assisting with one or more of the following: daily activities (eg, reading, cooking, cleaning, and shopping); driving/traveling with the patient to clinical appointments; being actively involved in clinical appointments; and influencing treatment decisions (eg, advising the patient or helping him or her to understand things and giving an opinion about the treatment he or she will receive). Recruitment of patients and caregivers was conducted using a combination of online recruitment (via the SSI website) and physician referral. Physicians identified suitable patients/caregivers and, with their consent, passed on their details to the research organization.
The questionnaire was divided into patient and caregiver sections (the questions are listed with the tables and figures in the “Results” section). The patient questionnaire comprised two modules. Module A included a number of questions related to initial symptoms, diagnosis (including first HCP visit), time since diagnosis, and information provided (including source). Module B included a number of questions related to treatment, follow-up, obstacles to managing wAMD, and emotional impact. The caregiver questionnaire was similar, but also included questions on type of support provided. Information on patient–caregiver relationship was also obtained.
Data collection and analysis
The responders (patients and caregivers) were asked to provide yes/no/not sure answers based on a number of available options or to rate questions using impact scales (positive impact, no impact, negative impact), dependency scales (not dependent, neither dependent nor independent, dependent), or convenience scales (not inconvenient, neither convenient nor inconvenient, inconvenient).
All completed questionnaire data were stored and captured in SPSS format (SPSS Inc., Chicago, IL, USA). Prior to analyses, data checks were undertaken to ensure that all responders met the screening criteria; only eligible responders answered relevant questions, responders who clicked through the survey without giving thoughtful responses were removed, and outliers were removed from relevant questions.
All data were presented as descriptive statistics based on absolute percentages and means. Where possible, data were stratified according to whether patients had wAMD in one or two eyes, and these data were compared and analyzed using either a two-sided t-test (to compare mean values) or two-tailed Z-test (to compare percentages). These analyses were based on the assumption of equal variance with a 5% significance level (P<0.05). Tests were adjusted using the Bonferroni correction to counteract the problem of multiple and pairwise comparisons. Data analyses were performed in SPSS version 21, and all analyses were documented in syntax files.
A total of 910 patients with wAMD and 890 caregivers completed the questionnaire. The majority of patients (82.1%; n=747/910) received support from a caregiver. The caregivers included in the survey were a child or grandchild of the patient (47.3%; n=421/890), partner (23.3%; n=207/890), neighbor/friend/other relatives (13.7%; n=122/890), sibling (6.0%; n=53/890), or volunteer (3.3%; n=29/890). Only 6.5% (n=58/890) were professional (paid) caregivers. The majority of caregivers (63.0%; n=561/890) also lived with the patient.
Current approaches to wAMD management
wAMD was diagnosed in two eyes in 45.1% (n=410/910) of patients and in one eye in 54.9% (n=500/910) of patients. The majority of patients (74.7%; n=680/910) had been diagnosed with wAMD for >1 year (Table 1). Most patients (72.9%; n=663/910) visited an HCP within 1 month of first noticing a change in vision (Table 1). Nearly half of all patients (41.2%; n=187/454) who delayed visiting an HCP thought that the symptoms would resolve. Significantly more patients with wAMD in one eye delayed visiting an HCP, as they were unaware that their vision had changed (9.4% [n=23/245] vs 2.4% [n=5/209]; P<0.05) (Table 1). Patients with wAMD in two eyes were more likely to be diagnosed earlier (ie, 1–3 weeks) than the patients with wAMD in one eye (33.9% [n=139/410] vs 27.2% [n=136/500], respectively; P<0.05) (Table 1).
Treatment and follow-up
The majority of patients (63.8%; n=581/910) had been receiving anti-VEGF injections for >1 year (Table 2). Anti-VEGF injections had been started immediately in 54.4% (n=495/910) of patients, and this number was significantly higher in those with wAMD in two eyes compared with one eye (62.0% [n=254/410] vs 48.2% [n=241/500], respectively; P<0.05). Patients usually attended check-ups every 4–6 weeks (42.3%; n=385/910). Patients with wAMD in two eyes were more likely to attend more frequently (every 2 months) compared with patients with wAMD in one eye (33.4% [n=137/410] vs 25.4% [n=127/500]; P<0.05). Significantly more patients with wAMD in two eyes compared with one eye had injections at every visit (55.4% [n=227/410] vs 32.0% [n=160/500]; P<0.05). A temporary improvement or stabilization in vision as a result of current treatment was reported by 51.6% of patients (n=470/910), and 22.3% of patients (n=203/910) reported a return to prediagnosis vision or that their vision was still improving.
Most caregivers always attended appointments (60.1%; n=535/890) and were involved in discussions about the treatment plan (83.3%; n=555/666; Table 3). Many caregivers were able to reduce the level of domestic assistance provided after the patient started treatment (30.2%; n=269/890), with many also reporting that the patient had a temporary improvement or stabilization in their vision (53.4%; n=475/890). However, a number of caregivers reported that frequent appointments were inconvenient (Figure 1).
Table 3 Treatment and follow-up of wet age-related macular degeneration from a caregiver perspective
Information and support programs
The level and source of information on wAMD that had been provided is summarized in Table 4. The main source of information for both patients (75.6%; n=688/910) and caregivers (71.6%; n=637/890) was the physician, followed by the Internet (8.6% [n=78/910] and 11.2% [n=100/890]). However, only 23.0% (n=209/910) of patients were enrolled in a patient support program that aimed to provide appointment reminders (72.2% [n=151/209]) and emotional support (58.9% [n=123/209]).
Table 4 Level of information and support provided based on patient and caregiver perspective
Obstacles to treatment
Most patients (65.4%; n=595/910) and caregivers (77.0%; n=685/890) reported a number of obstacles in managing wAMD (Figure 2). For patients, the main barrier was the treatment itself (34.8%; n=317/910) (this refers to anti-VEGF agents only, and the most common barriers would relate to having injections, frequency of injections, and possible injection-related side effects). Other barriers included treatment costs (27.8%; n=253/910) and finding the right treatment option (27.4%; n=249/910) (this refers to anti-VEGF agents and laser and relates to information on choosing the best option, including whether to have anti-VEGF injections [any type], issues relating to frequency of treatments, or if/when to have laser). Several obstacles were reported by a significantly higher proportion of patients with wAMD in two eyes compared with one eye, including the treatment itself (39.0% [n=160/410] vs 31.4% [n=157/500], respectively; P<0.05), and finding the right treatment option (35.1% [n=144/410] vs 21.0% [n=105/500]; P<0.05). However, 34.6% (n=315/910) of all patients also reported that they were willing to do whatever it takes to maintain their vision; this was significantly higher for patients with wAMD in one eye than those with wAMD in two eyes (43.8% [n=219/500] vs 23.4% [n=96/410]; P<0.05). For caregivers, the main barriers were also the patient’s treatment itself (38.8% [n=345/890]) and finding the right treatment option for the patient (31.0% [n=276/890]) (Figure 2).
Despite these obstacles, 84.3% (n=767/910) of patients and 74.2% (n=660/890) of caregivers reported that the patient was compliant with treatment (ie, attended every clinic appointment). For the 15.7% (n=143/910) of patients who missed a clinic appointment, the main obstacles were that the caregiver was unable to take them to the appointment (25.9%; n=37/143), fear about receiving an injection (21.0%; n=30/143), and patient illness (reason not stated) (18.9%; n=27/143).
Most patients (56.7%; n=516/910) were usually taken to the appointment by a caregiver; however, 20.4% (n=186/910) went by public transport, 12.4% (n=113/910) drove themselves, 8.1% (n=74/910) used a taxi, and 2.3% (n=21/910) were taken by an ambulance. Travel time to appointments, however, did not affect the impact that wAMD had on a patient’s life (Figure 3).
This global survey provided an overview of the diagnosis and management of wAMD and current barriers to treatment from the perspective of 1,800 patients and caregivers. Responders from nine countries were recruited via physician referral and the Internet, thus representing a broad cross-section of the wAMD cohort in a general population, and the distribution of patients with AMD in one or two eyes suggests that the sample was not skewed toward most severe patients only. Most patients had also been diagnosed (75%) and receiving anti-VEGF injections (64%) for >1 year; they were, therefore, a suitable sample to survey regarding issues related to long-term wAMD treatment. The study found that most patients (73%) had visited an HCP within 1 month of experiencing vision changes; however, fewer patients were diagnosed (43%) and treated (54%) during the first visit. Some patients also delayed visiting an HCP as they thought the symptoms would resolve (41%) or that it was part of the aging process (20%), with 20% being diagnosed between 1 and 2 months and 8% receiving delayed treatment.
Other studies have found that delaying diagnosis and subsequent treatment adversely affects the outcomes.11 In one study of patients with wAMD (1,149 eyes), those with a shorter waiting time between diagnosis and first injection (≤10 days) experienced a smaller loss of visual acuity and greater improvement after first treatment compared with those patients with a longer lag time (>10 days).12 Patients with wAMD who were treated early with anti-VEGF injections or usual care also incurred lower total direct costs over a lifetime, including incremental costs per vision-year gained ($15,279 vs $57,230, respectively) and quality-adjusted life years ($36,282 vs $132,281).13 Unfortunately, further evaluation of the impact of delayed diagnosis and treatment was beyond the scope of the current survey.
The survey also revealed that 42% of patients had check-ups every 4–6 weeks, and 43% received treatment at every visit. Overall, 84% of patients and 74% of caregivers reported that the patient was compliant with treatment (ie, attended every clinic appointment). Vision had improved as a result of treatment, with 74% of patients and 71% of caregivers reporting a return to prediagnosis vision, vision still improving, temporary improvement, or stabilization. In addition, 30% of caregivers reduced the level of care provided following patient treatment. Unfortunately, this survey did not monitor the costs associated with patient care and treatment patterns, but a US survey of 803 responders highlighted that the annual costs of caregiving (paid and unpaid) ranged from $225 to $47,086, depending on visual acuity.14
Despite the treatment benefits described here, many patients and caregivers reported a number of obstacles associated with wAMD management that were related to 1) the treatment itself (reasons not stated), 2) finding the right option, and 3) treatment costs. These three obstacles were comparable between patients and caregivers but were significantly higher in patients with wAMD in two eyes compared with one eye. Patients with wAMD in one eye were significantly more likely to do whatever it takes to maintain their vision and to report that there were no obstacles associated with wAMD management. These differences may be linked to the emotional impact of wAMD (particularly the level of depression and disease severity), which is discussed elsewhere.15
Current evidence has shown that monthly and as-needed anti-VEGF treatment regimens with ranibizumab are effective,7,8 though it might be difficult to replicate monthly clinical regimens in real-life settings.16 In the AURA study, which followed 2,227 patients who received one or more ranibizumab injections for up to 2 years, there were fewer injections administered compared with clinical studies (the mean was 5.0 [year 1] and 2.2 [year 2]); the initial improvement observed in visual acuity was not maintained over time, and there was a return to near-baseline values by year 2.17 In an attempt to address these issues, two studies focused on quarterly versus monthly dosing with ranibizumab, and though both were effective in ETDRS letters gained, the results with quarterly dosing were less impressive compared with monthly dosing.18,19 Unfortunately, the current survey did not explore the effect of different dosing regimens on compliance and treatment barriers, but a different approach (such as treat-and-extend) could address some of the issues raised by the responders.
Not surprisingly, inadequate information on wAMD was also perceived as a barrier by 11% of patients and 16% of caregivers, with 16% of patients and 25% of caregivers highlighting a lack of understanding about the disease as an issue. Teleconsultation networks have been used successfully in Italian practices, particularly in minimizing the delay between retreatments.20 This survey highlights the lack of professional patient support and treatment delays, and both could be further examined in a larger study on the role of telemedicine or with similar initiatives.
Although the survey is valuable in providing an overview of the impact of wAMD on patients and caregivers, it does have a number of limitations inherent with the observational and retrospective design. The questionnaire was devised by experts to cover all aspects of wAMD, but it is not validated and it is still subjective, and some questions may be perceived differently by responders from different countries. The questionnaire did not quantify some of the obstacles associated with wAMD management, and the results may therefore have a number of biases, including selection bias based on the exclusion of nonresponders. It is also not possible to distinguish the severity of the outcomes reported, and it did not include a control. However, the large sample size and use of physician and online referral would capture a wide sample, as shown by the distribution of patients with wAMD in one or two eyes.
In summary, the findings from this survey give a useful overview of the diagnosis, management, and barriers to treatment for wAMD from a patient and caregiver perspective. The results highlight that education in symptom awareness, wider provision of information and support, and tailoring long-term follow-up to adjust for difficulties associated with monthly clinic visits and injections are key areas for improvement.
These data have been presented at the Royal College of Ophthalmologists’ Congress (May 20–22, 2014, Birmingham, UK), the German Retina Society Congress (June 13–14, 2014, Düsseldorf, Germany) and the International Society for Pharmacoeconomics and Outcomes Research (November 8–12, 2014, Amsterdam, the Netherlands). The contribution of the IRCCS Fondazione Bietti to this paper was supported by the Italian Ministry of Health and by Fondazione Roma. The survey was sponsored by Bayer HealthCare Pharmaceuticals. Medical writing assistance was provided by PAREXEL and was funded by Bayer HealthCare Pharmaceuticals.
Monica Varano has served on advisory boards for Bayer, Novartis, and Allergan. Nicole Eter, Steve Winyard, and Rafael Navarro report no conflicts of interest in this study. Kim U Wittrup-Jensen is an employee of Bayer Pharma AG. Julie Heraghty is a CEO of Macular Disease Foundation Australia, which receives funding from Bayer and Novartis.
Cardarelli WJ, Smith RA. Managed care implications of age-related ocular conditions. Am J Manag Care. 2013;19(5 suppl):S85–S91.
Schmier JK, Jones ML, Halpern MT. The burden of age-related macular degeneration. Pharmacoeconomics. 2006;24(4):319–334.
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106– e116.
Acess Economics. The Global Economic Cost of Visual Impairment. International Council of Ophthalmology Web site. Available from: http://www.icoph.org/dynamic/attachments/resources/globalcostofvi_finalreport.pdf. Accessed October 6, 2014.
Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201.
Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444.
Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431.
Holekamp NM, Liu Y, Yeh WS, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014;157(4):825–833.
Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S. Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration. PLoS One. 2015;10(6):e0129361.
Real JP, Luna JD, Urrets-Zavalia JA, De Santis MO, Palma SD, Granero GE. Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration. Eur J Ophthalmol. 2013;23(6):857–864.
Matthe E, Sandner D. Frühzeitige behandlung mit ranibizumab (Lucentis®) bei exsudativer AMD. Ophthalmologe. 2011;108(3):237–243.
Javitt JC, Zlateva GP, Earnshaw SR, et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008;11(4):563–574.
Schmier JK, Halpern MT, Covert D, Delgado J, Sharma S. Impact of visual impairment on use of care giving by individuals with age-related macular degeneration. Retina. 2006;26(9):1056–1062.
Gopinath B, Kifley A, Cummins R, Heraghty J, Mitchell P. Predictors of psychological distress in caregivers of older persons with wet age-related macular degeneration. Aging Ment Health. 2015;19(3):239–246.
Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol. 2014;158(3):537–543.
Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2014;99(2):220–226.
Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239–248.
Schmidt-Erfurth U, Eldem B, Guymer R, et al; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831–839.
Azzolini C, Torreggiani A, Eandi C, et al. A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases. J Telemed Telecare. 2013;19(8):437–442.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.